Abstract:Parkinson's Disease (PD) is a chronic neurodegenerative disorder characterized by motor deficits which result from the progressive loss of dopaminergic neurons. Gene therapy using growth factors such as VEGF seems to be a viable approach for potential therapeutic treatment of PD. In this study, we utilized a novel non-viral gene carrier designated as PEI-PLL synthesized by our laboratory to deliver VEGF gene to study its effect by using both cell culture as well as animal models of PD. For cell culture experiments, we utilized 6-hydroxydopamine (6-OHDA) mediated cell death model of MN9D cells following transfection with either a control plasmid or VEGF expressing plasmid. As compared to control transfected cells, PEI-PLL mediated VEGF gene delivery to MN9D cells resulted in increased cell viability, increase in the number of Tyrosine hydroxylase (TH) positive cells and decreased apoptosis following 6-OHDA insult. Next, we studied the therapeutic potential of PEI-PLL mediated VEGF gene delivery in SNPc by using unilateral 6-OHDA Medial forebrain bundle (MFB) lesion model of PD in rats. VEGF administration prevented the loss of motor functions induced by 6-OHDA as determined by behavior analysis. Similarly, VEGF inhibited the 6-OHDA mediated loss of DA neurons in Substantia Nigra Pars Compacta (SNPc) as well as DA nerve fibers in striatum as determined by TH immunostaining. In addition, PEI-PLL mediated VEGF gene delivery also prevented apoptosis and microglial activation in PD rat models. Together, these results clearly demonstrated the beneficial effects of PEI-PLL mediated VEGF gene delivery on dopaminergic system in both cell culture and animal models of PD.Statement of SignificanceIn this report, we exploited the potential of PEI-PLL to deliver VEGF gene for the potential therapeutic treatment of PD by using both cell culture and animal models of PD. To the best of our knowledge, this is the first report describing the use of novel polymeric gene carriers for the delivery of VEGF gene to DA neurons with improved transfection efficiency. Finally, the study will lead to a significant advancement in the field of non-viral PD gene therapy treatment. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Angiopep-Conjugated Nanoparticles for Targeted Long-Term Gene Therapy of Parkinson’s Disease

An Antisense Oligonucleotide-Loaded Blood–Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson’s Disease

Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model.

Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.

Neuroprotection in a 6‐hydroxydopamine‐lesioned Parkinson Model Using Lactoferrin‐modified Nanoparticles

Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson’s Disease

Highly Branched Poly(β-Amino Ester) Delivery of Minicircle DNA for Transfection of Neurodegenerative Disease Related Cells

Targeted Liposomal Co-Delivery Dopamine with 3-n-Butylphthalide for Effective Against Parkinson's Disease in Mice Model

Brain-targeted Gene Delivery of ZnO Quantum Dots Nanoplatform for the Treatment of Parkinson Disease

Neuroprotective Effect of Chitosan Nanoparticle Gene Delivery System Grafted with Acteoside (ACT) in Parkinson’s Disease Models

Delayed Gene Therapy of Glial Cell Line-Derived Neurotrophic Factor is Efficacious in a Rat Model of Parkinson's Disease.

A bacteria deriving peptide modified dendrigraft poly-l-lysines (DGL) self-assembling nanoplatform for targeted gene delivery.

A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery.

NIR‐Assisted MgO‐Based Polydopamine Nanoparticles for Targeted Treatment of Parkinson's Disease Through the Blood‐Brain Barrier

Protective Effects of Intracerebral Adenoviral-Mediated GDNF Gene Transfer in a Rat Model of Parkinson's Disease

Synthesis Of Double Interfering Biodegradable Nano-Mgo Micelle Composites And Their Effect On Parkinson'S Disease

Enhanced Blood-Brain Barrier Penetration and Glioma Therapy Mediated by A New Peptide Modified Gene Delivery System

Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.

Polylysine-modified Polyethylenimine (PEI-PLL) Mediated VEGF Gene Delivery Protects Dopaminergic Neurons in Cell Culture and in Rat Models of Parkinson's Disease (PD).

A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease

A Preliminary Study of Parkinson's Gene Therapy Via Sono-Magnetic Sensing Gene Vector for Conquering Extra/intracellular Barriers in Mice